142 related articles for article (PubMed ID: 26808161)
1. The role of glucuronidation in drug resistance.
Mazerska Z; Mróz A; Pawłowska M; Augustin E
Pharmacol Ther; 2016 Mar; 159():35-55. PubMed ID: 26808161
[TBL] [Abstract][Full Text] [Related]
2. [Glucuronidation of antitumour therapeutics--detoxification, mechanism of resistance or prodrug formation?].
Mróz A; Mazerska Z
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1462-77. PubMed ID: 27259218
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of human UDP-glucuronosyltransferase genes.
Hu DG; Meech R; McKinnon RA; Mackenzie PI
Drug Metab Rev; 2014 Nov; 46(4):421-58. PubMed ID: 25336387
[TBL] [Abstract][Full Text] [Related]
4. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Cummings J; Ethell BT; Jardine L; Boyd G; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Cancer Res; 2003 Dec; 63(23):8443-50. PubMed ID: 14679008
[TBL] [Abstract][Full Text] [Related]
5. Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
Sun H; Zhang T; Wu Z; Wu B
J Pharm Sci; 2015 Jan; 104(1):244-56. PubMed ID: 25393417
[TBL] [Abstract][Full Text] [Related]
6. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Liu W; Feng Q; Li Y; Ye L; Hu M; Liu Z
Toxicol Appl Pharmacol; 2012 Dec; 265(3):316-24. PubMed ID: 22982073
[TBL] [Abstract][Full Text] [Related]
7. Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications.
Bock KW
Biochem Pharmacol; 2015 Jul; 96(2):77-82. PubMed ID: 25937523
[TBL] [Abstract][Full Text] [Related]
8. From differential induction of UDP-glucuronosyltransferases in rat liver to characterization of responsible ligand-activated transcription factors, and their multilevel crosstalk in humans.
Bock KW
Biochem Pharmacol; 2011 Jul; 82(1):9-16. PubMed ID: 21420387
[TBL] [Abstract][Full Text] [Related]
9. Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention.
Saracino MR; Lampe JW
Nutr Cancer; 2007; 59(2):121-41. PubMed ID: 18001207
[TBL] [Abstract][Full Text] [Related]
10. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
11. Roles of UDP-glucuronosyltransferases in chemical carcinogenesis.
Bock KW
Crit Rev Biochem Mol Biol; 1991; 26(2):129-50. PubMed ID: 1914494
[TBL] [Abstract][Full Text] [Related]
12. Human UDP-glucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics.
Zhang H; Patana AS; Mackenzie PI; Ikushiro S; Goldman A; Finel M
Drug Metab Dispos; 2012 Oct; 40(10):1935-44. PubMed ID: 22782802
[TBL] [Abstract][Full Text] [Related]
13. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes.
Bourcier K; Hyland R; Kempshall S; Jones R; Maximilien J; Irvine N; Jones B
Drug Metab Dispos; 2010 Jun; 38(6):923-9. PubMed ID: 20304965
[TBL] [Abstract][Full Text] [Related]
14. Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways.
Shelby MK; Klaassen CD
Drug Metab Dispos; 2006 Oct; 34(10):1772-8. PubMed ID: 16855052
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
[TBL] [Abstract][Full Text] [Related]
16. Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.
Margaillan G; Rouleau M; Klein K; Fallon JK; Caron P; Villeneuve L; Smith PC; Zanger UM; Guillemette C
Drug Metab Dispos; 2015 Sep; 43(9):1331-5. PubMed ID: 26076694
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.
Mutlib AE; Goosen TC; Bauman JN; Williams JA; Kulkarni S; Kostrubsky S
Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.
Zahreddine HA; Borden KL
Clin Cancer Res; 2015 May; 21(10):2207-10. PubMed ID: 25810373
[TBL] [Abstract][Full Text] [Related]
19. [Drug glucuronidation and disposition in brain].
Zhang ZQ; Sheng L; Li Y
Yao Xue Xue Bao; 2016 Nov; 51(11):1674-80. PubMed ID: 29908109
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3.
Jeong ES; Kim YW; Kim HJ; Shin HJ; Shin JG; Kim KH; Chi YH; Paik SH; Kim DH
Xenobiotica; 2015 Jan; 45(1):10-8. PubMed ID: 25034008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
